Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest/Pierre Fabre now aiming for Q4 levomilnacipran MDD filing

This article was originally published in Scrip

Executive Summary

Forest Laboratories and Pierre Fabre Medicament plan to file a new drug application (NDA) for levomilnacipran for the treatment of adults with major depressive disorder (MDD) with the US FDA by the end of this year, after the third out of four Phase III trials produced positive top-line results. This timing is a little later than the mid-2012 date previously given, and follows a difficult development programme with the product.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts